Clinical Report: Induction Immunochemotherapy and CCRT in Unresectable Esophageal Cancer

Overview

This systematic review and meta-analysis demonstrate that induction immunochemotherapy combined with concurrent chemoradiotherapy (ICT-CCRT) significantly improves overall survival (OS) in patients with unresectable esophageal cancer compared to CCRT alone. Additionally, CCRT combined with consolidation immunotherapy (CCRT-IO) enhances progression-free survival (PFS), although its OS benefits are less pronounced.

Background

Unresectable esophageal cancer presents significant treatment challenges, with conventional approaches primarily relying on concurrent chemoradiotherapy (CCRT). The integration of immunotherapy into treatment regimens has emerged as a potential strategy to improve patient outcomes, yet its clinical efficacy remains under investigation. Understanding the impact of these combinations on survival metrics is crucial for optimizing treatment protocols.

Data Highlights

Key Findings

• ICT-CCRT significantly enhances OS compared to CCRT alone (HR 0.52).
• CCRT-IO improves PFS consistently across analyses (HR 0.74).
• In network meta-analysis, ICT-CCRT ranked highest for both OS and PFS.
• CCRT-IO shows OS benefits only in pairwise analyses.
• Insufficient randomized controlled trials exist to validate these findings.

Clinical Implications

The findings suggest that incorporating induction immunochemotherapy into treatment regimens for unresectable esophageal cancer may lead to improved survival outcomes. Clinicians should consider these combinations while remaining aware of the need for further validation through randomized trials.

Conclusion

In conclusion, the integration of immunotherapy with CCRT shows promise in enhancing survival outcomes for patients with unresectable esophageal cancer, warranting further investigation to establish optimal treatment protocols.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
2. The ASCO Post, 2026 -- Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
3. Frontiers in Oncology, 2026 -- Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study
4. ESMO Clinical Practice Guideline, 2025 -- Interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
5. the asco post — Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
6. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
7. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma - ScienceDirect
8. Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-term Follow-up of a Prospective Randomized Trial (RTOG 85-01) | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network